{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053248","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.796421+00:00","generated_at":"2026-06-02T21:51:18.562225+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months","bullets":["Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.","86% (3mg) and 80% (2mg) patients stable/improved vs 70% control; 0% (3mg) worsened ≥2-step vs 10% control.","No drug-related serious adverse events reported; favorable safety profile maintained.","Company on track for Phase 3 wet AMD trial (LUGANO) in H2 2024 and DME trial (VERONA) data in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053248","json":"https://secwatch.observer/filing/0000950170-24-053248.json","markdown":"https://secwatch.observer/filing/0000950170-24-053248.md","text":"https://secwatch.observer/filing/0000950170-24-053248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/0000950170-24-053248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/eypt-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:51:18.562225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}